All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub

Brought to you by Scientific Education Support

Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My AML Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View AML content recommended for you

#ASCO23

Share:

Jun 2, 2023

X post image

11 Jun 2023

#ASCO23 | Poster
Kendall Diebold @UABNews discussed findings that 3-day condensed schedule of cytarabine gives earlier hematopoetic recovery and is as safe as standard 5-day schedule.
#leusm

X post image

7 Jun 2023

#ASCO23 | Education session
Richard Jirui Lin @MSKCancerCenter discussed factors to consider when selecting older patients for HSCT, and what can be done to optimize outcomes.
#leusm #AMLsm

X post image

7 Jun 2023

#ASCO23 | Education session
A memorable presentation from Gabriel N. Mannis @StanfordMed on the use of venetoclax+HMA firstline, with tips for toxicity management and provision of supportive care.
#leusm #AMLsm

X post image

7 Jun 2023

#ASCO23 | Education session
@KatieLaiMD_MPH @PennMedicine summarized the current treatment options with BCL2, FLT3 and IDH inhibitors, including doublet and triplet combinations going through clinical trials.
#leusm #AMLsm

X post image

6 Jun 2023

#ASCO23 | Poster
Stéphane De Botton @GustaveRoussy discusses updated longer-term data from Ph 3 AGILE trial of IVO+AZA vs PBO vs AZA in IDH1-mut AML:
- OS 20.3 months vs 7.9
- Rapid blood count recovery
- Higher rate of transfusion independence
#leusm

X post image

6 Jun 2023

#ASCO23 | Education session
Michael Heuser @MHH_life presents a summary of the value of MRD, including clinical timepoints where MRD information can feed into and impact treatment decisions.
#leusm

X post image

5 Jun 2023

CONGRESS| #ASCO23 Catherine Smith @UCSFCancer summarizes a phase 1/2 study evaluating patients treated with ZNd5+azenosertib for R/R AML. This study is enrolling across the US and aims to assess safety and determine the MTD and RP2D for this combination treatment. #AMLsm

X post image

5 Jun 2023

CONGRESS|#ASCO23 @NicholasShortMD @MDAndersonNews describes a study evaluating vibecotamab in patients with MRD+AML and MDS/CMML post HMA failure. The aim of the study is to determine MRD negativity rate post 4 cycles of vibecotamab of 50% and ORR of 30% #AMLsm

X post image

5 Jun 2023

CONGRESS|#ASCO23 Douglas Faller presents the FRIDA study; investigating dose escalation and expansion of Iadedemstat+gilteritinib in patients with FLT3mut+ AML to understand safety and RPD2. This trial is accruing and the first cohort completed through the escalation phase #AMLsm

X post image

5 Jun 2023

CONGRESS |#ASCO23 Omer Jamy @UABHemOncFellow presents an upcoming study investigating OS in patients with AML after second-line salvage therapy treated with GPS compared to investigators best available therapy. This study will also explore the safety and tolerability GPS #AMLsm

X post image

5 Jun 2023

CONGRESS |#ASCO23 @Daver_Leukemia @MDAndersonNews summarizes 2 expansion cohort studies investigating PVEK+AZA+VEN in first-line AML therapy and PVEK+magrolimab in patients with R/R AML. Previous studies have shown treatments to be well tolerated but require further study #AMLsm

X post image

5 Jun 2023

CONGRESS| #ASCO23 Uday Popat @MDAndersonNews follows up from previous data validating fractionation of busulfan to see if this could reduce toxicity, lower NRM and not increase relapse risk. Results showed patients achieved lower toxicity without increasing relapse risk #AMLsm

X post image

5 Jun 2023

CONGRESS|#ASCO23 Amer Zeidan @YaleMed presents an analysis on patients with AML who started first-line treatment after 2018 and received ≥ treatment with VEN at any point. Median OS was longer in patients with de novo AML who received VEN vs patients who were pre-treated #AMLsm

X post image

5 Jun 2023

CONGRESS| #ASCO23 @JustinWattsMD @UMiamiHealth discusses an analysis of patients with mIDH1 R/R AML who presented an exceptional response to treatment (DOR>12 months). Low mutational burden, and progressive reduction of mIDH1 VAF was associated with exceptional responses #AMLsm

X post image

5 Jun 2023

CONGRESS| #ASCO23 @LisaHicks @UnityHealthTO discusses how to recognize and manage patients at risk of COVID-19 with hematologic malignancies. Teaching patients how to recognise COVID-19 and starting a COVID-19 plan can help manage patients at at risk #AMLsm #AML #leukemia

X post image

5 Jun 2023

CONGRESS| #ASCO23 @LindseyBaden summarizes prevention strategies against COVID-19. Future preventative methods should focus on optimizing pre-exposure prophylaxis, identifying and treating early and keeping engagement in preventative strategies. #AMLsm #AML #leukemia

X post image

5 Jun 2023

CONGRESS | #ASCO23 | POSTER
@MariaAmaya_27 presents results from phase I dose escalation study of all-oral regimen of CC-486+venetoclax in R/R AML showing favorable safety profile and clinical responses (2 complete remissions is and 3 patients bridged to HSCT). See below👇 #leusm

X post image

5 Jun 2023

CONGRESS | #ASCO23 | Poster
Pierre Peterlin discusses results from phase I first-in-human trial of #tocilizumab + standard induction chemotherapy in newly diagnosed AML (TOCILAM). This combination appeared safe with high CR rate (n=9/10) & biological effect. #leusm

X post image

5 Jun 2023

#ASCO23 | Sandeep Gurbuxan @UChicagoPath shared a helpful summary of updates to the classification of AML (WHO-5 and ICC), using patient cases to illustrate why understanding the genetic profile is key. #leusm

X post image

5 Jun 2023

CONGRESS|#ASCO23
Jorge Cortes presents 5 year follow-up results from NCT01696084 showing longer median OS and EFS in older adults with CXP-351 vs 7+3. Median OS was greatest in low blast subgroups, CR rates were higher with CPX irrespective of baseline BM blasts. #leusm

X post image

3 Jun 2023

CONGRESS|#ASCO23|Poster
Andrew Hantel,@DanaFarber presented racial disparities in the uptake of novel therapies within 24-months of FDA approval for adult pts with AML. In a large database, white pts were more likely to receive novel therapy compared to persons of color
#leusm

X post image

2 Jun 2023

RT @ALL_Hub_: CONGRESS| #ASCO23| Anthony Stein,@cityofhope reported preliminary results from the first in-human trial evaluating SAR443579…

X post image

31 May 2023

🗣 #ASCO23 | The #AML Hub will be virtually covering the 2023 ASCO Annual Meeting.

📅 June 2–6, 2023
📍 Chicago, US and online

Watch our socials for live updates throughout the congress!

#leukemia #cancerawareness

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASCO 2023 American Society of Clinical Oncology

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Clinical trials in AML - match patients with relevant trials

Newsletter

Subscribe to get the best content delivered to your inbox